SNS 401 NG
Alternative Names: MPCvV phage - Sensei Biotherapeutics; SNS-401; SNS-401-NGLatest Information Update: 06 Jul 2021
At a glance
- Originator Sensei Biotherapeutics
- Developer Sensei Biotherapeutics; University of Washington
- Class Antineoplastics; Bacteriophages; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Merkel cell carcinoma
Most Recent Events
- 28 Jun 2021 Sensei Biotherapeutics announces intention to submit an IND application to the US FDA for Merkel cell carcinoma in the first half of 2022
- 28 Jun 2021 Sensei plans a broader basket study for Head and neck cancer, Lung cancer, Malignant melanoma, and triple negative Breast cancer based on the prevalence of Phortress antigens, if clinical proof of concept is achieved
- 28 Jun 2021 Sensei Biotherapeutics announces intention to initiate IND-enabling studies for Merkel cell carcinoma in USA, in the second half of 2022